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The central nucleus of  the amygdala (CEA) seems to be selectively involved in the 
passive component of  the behavioral (immobility) and the accompanying parasympa- 
thetic response (bradycardia) during conditioned environmental challenges,' leaving 
conditioned sympathetic, adreno-medullary, and adreno-cortical responses unaffected 
(Roozendaal et al., in preparation). Robust monosynaptic, .peptidergic connections to 
the vagal complex and periaqueductal gray may be mediating these effects. 
Intracerebroventricularly administered arginine-8-vasopressin (AVP) potentiates 
these stress-induced bradycardiac and immobility responses.* AVP may exert these 
effects via AVP and/or  oxytocin (OT) receptive systems in the CEA.' Microinfusion 
of AVP (dissolved in 1 p1  artificial CSF) into the CEA of conscious male Wistar rats 
under resting conditions, leads to a dose-dependent change in heart rate and behavior: 
A high dose of  AVP (2 ng), but not lower ones (20 and 200 pg),  causes a transient 
increase in heart rate and behavioral a~tivity.~  Moreover, in a part of the animals, the 
low dose of AVP even causes an opposite effect, that is, bradycardia. OT  administration 
(2 ng) induces responses similar to those induced with the high dose of  AVP. Neither 
plasma norepinephrine nor epinephrine is influenced after AVP infusion, suggesting 
that the tachycardia is due to reduced parasympathetic control, rather than a stimula- 
tion of the sympathetic outflow. The effects of AVP and OT during conditioned stress 
were studied in male Roman high-avoidance (RHA) and Roman low-avoidance. (RLA) 
rats, selected genetically for shuttle-box acquisition behavior. In RLA rats the cardiac 
and behavioral responses to the emotional stressor are bradycardia and immobility, 
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suggesting an important role of the CEA in these rats. The RHA rats, however, fail to 
show  any  change in  heart  rate or immobility in response to a  conditioned  stress 
situation. The low dose of AVP in the CEA of conscious RLA rats causes an enhance- 
ment of the stress-induced bradycardiac and immobility response. However, the high 
dose of  AVP (2 ng)  and  OT (200  pg)  attenuate the bradycardiac  and  immobility 
response in the RLA rats. As expected, infusion of AVP and OT in the RHA rats fails 
to induce any change in heart  rate or immobility. Binding studies revealed that in 
contrast to the selective and highly potent AVP receptor, the OT receptor recognizes 
AVP and OT with similar affinit~.~  This suggests that the behavioral and autonomic 
responses of  the high dose of  AVP may be caused by OT receptor activation. 
In conclusion, central  amygdaloid vasopressinergic and oxytocinergic receptor- 
mediated mechanisms seem to exert opposite effects on the regulation of stress-induced 
autonomic and behavioral responses. AVP enhances the passive components of  the 
conditioned stress response. The oxytocinergic system attenuates the CEA output. The 
stimulating role of AVP in passive coping may be general and has also been reported 
in other brain regions. The differences between RLA and RHA males suggest that 
these peptidergic mechanisms are only active in rats that preferentially adopt a passive 
coping strategy.2 
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